Mitochondria in Cancer Metabolism, an Organelle Whose Time Has Come?

Overview

Journal Biochim Biophys Acta Rev Cancer

Publisher Elsevier

Specialties Biochemistry
Biophysics
Oncology

Date 2018 May 29

PMID 29807044

Citations 30

Authors

Rebecca G Anderson

Lais P Ghiraldeli

Timothy S Pardee

Affiliations

Soon will be listed here.

Abstract

Mitochondria have long been controversial organelles in cancer. Early discoveries in cancer metabolism placed much emphasis on cytosolic contributions. Initial debate focused on if mitochondria had a role in cancer formation and progression at all. More recently the contributions of mitochondria to cancer development and progression have become firmly established. This has led to the identification of novel targets and inhibitors being studied as new therapeutic approaches. This review will summarize the role of mitochondria in cancer and highlight several agents under development.

Citing Articles

SLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α.

Yu H, Bai L, Jin L, Zhang Y, Xi Z, Wang D Cell Commun Signal. 2025; 23(1):130.

PMID: 40065301 PMC: 11895242. DOI: 10.1186/s12964-025-02109-y.

Emerging Paradigms in Cancer Metastasis: Ghost Mitochondria, Vasculogenic Mimicry, and Polyploid Giant Cancer Cells.

Krotofil M, Tota M, Siednienko J, Donizy P Cancers (Basel). 2024; 16(20).

PMID: 39456632 PMC: 11506636. DOI: 10.3390/cancers16203539.

Characterization of mitochondrial metabolism related molecular subtypes and immune infiltration in colorectal adenocarcinoma.

Wang M, Xue L, Fei Z, Luo L, Zhang K, Gao Y Sci Rep. 2024; 14(1):24326.

PMID: 39414905 PMC: 11484867. DOI: 10.1038/s41598-024-75482-2.

Multifaceted role of GCN2 in tumor adaptation and therapeutic targeting.

Chen C, Xie Y, Qian S Transl Oncol. 2024; 49:102096.

PMID: 39178574 PMC: 11388189. DOI: 10.1016/j.tranon.2024.102096.

Integrated multi-omics analysis and machine learning developed a prognostic model based on mitochondrial function in a large multicenter cohort for Gastric Cancer.

Ma Y, Jin J, Xue Z, Zhao J, Cai W, Zhang W J Transl Med. 2024; 22(1):381.

PMID: 38654380 PMC: 11040813. DOI: 10.1186/s12967-024-05109-7.

References

Choi Y, Lim I . Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells. Cancer Lett. 2014; 346(2):300-8. DOI: 10.1016/j.canlet.2014.01.015. View

Abate C, Patel L, Rauscher 3rd F, Curran T . Redox regulation of fos and jun DNA-binding activity in vitro. Science. 1990; 249(4973):1157-61. DOI: 10.1126/science.2118682. View

Park H, Lee J, Lim J, Jo D, Park S, Suh P . Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim. BMC Cancer. 2014; 14:431. PMC: 4072609. DOI: 10.1186/1471-2407-14-431. View

Velez J, Pan R, Lee J, Enciso L, Suarez M, Duque J . Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget. 2016; 7(32):51435-51449. PMC: 5239486. DOI: 10.18632/oncotarget.9843. View

Michelakis E, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E . Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010; 2(31):31ra34. DOI: 10.1126/scitranslmed.3000677. View

Archer S . Mitochondrial dynamics--mitochondrial fission and fusion in human diseases. N Engl J Med. 2013; 369(23):2236-51. DOI: 10.1056/NEJMra1215233. View

Wang J, Hansen K, Edwards R, Van Houten B, Qian W . Mitochondrial division inhibitor 1 (mdivi-1) enhances death receptor-mediated apoptosis in human ovarian cancer cells. Biochem Biophys Res Commun. 2014; 456(1):7-12. PMC: 4297922. DOI: 10.1016/j.bbrc.2014.11.010. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z . Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011; 20(5):674-88. PMC: 3221282. DOI: 10.1016/j.ccr.2011.10.015. View

10.

Cassidy-Stone A, Chipuk J, Ingerman E, Song C, Yoo C, Kuwana T . Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell. 2008; 14(2):193-204. PMC: 2267902. DOI: 10.1016/j.devcel.2007.11.019. View

11.

Petrachi T, Romagnani A, Albini A, Longo C, Argenziano G, Grisendi G . Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget. 2016; 8(4):6914-6928. PMC: 5351679. DOI: 10.18632/oncotarget.14321. View

12.

Fan J, Shan C, Kang H, Elf S, Xie J, Tucker M . Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell. 2014; 53(4):534-48. PMC: 3943932. DOI: 10.1016/j.molcel.2013.12.026. View

13.

Kang J, Lee S, Lee J, Nam B, Seong T, Son J . Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion. Oncotarget. 2016; 7(31):49397-49410. PMC: 5226516. DOI: 10.18632/oncotarget.10354. View

14.

Jiang H, Lwin T, Zhao X, Ren Y, Li G, Moscinski L . Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma. Br J Haematol. 2018; 184(2):298-302. PMC: 6066460. DOI: 10.1111/bjh.15079. View

15.

Sun R, Board P, Blackburn A . Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Mol Cancer. 2011; 10:142. PMC: 3240126. DOI: 10.1186/1476-4598-10-142. View

16.

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

17.

Morais R, Zinkewich-Peotti K, Parent M, Wang H, Babai F, ZOLLINGER M . Tumor-forming ability in athymic nude mice of human cell lines devoid of mitochondrial DNA. Cancer Res. 1994; 54(14):3889-96. View

18.

Gharanei M, Hussain A, Janneh O, Maddock H . Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. PLoS One. 2013; 8(10):e77713. PMC: 3798380. DOI: 10.1371/journal.pone.0077713. View

19.

Jackson A, Sun W, Kilgore J, Guo H, Fang Z, Yin Y . Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer. Oncotarget. 2017; 8(59):100113-100127. PMC: 5725006. DOI: 10.18632/oncotarget.22012. View

20.

Selak M, Armour S, MacKenzie E, Boulahbel H, Watson D, Mansfield K . Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005; 7(1):77-85. DOI: 10.1016/j.ccr.2004.11.022. View